Because tirzepatide stays in your system for several days (it has a half-life of about 5 days), your healthcare team may need to monitor and treat your symptoms over time
*Correspondence: Yu Wang, [email protected] These authors have contributed equally to this work This article was submitted to Clinical Diabetes, a section of the journal Frontiers in Endocrinology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Our top picks New
Nausea, vomiting, diarrhea, and constipation occur in 20 to 40 percent of patients, typically resolving as the body adapts
They are not interchangeable in research design
A: Long-term value means limiting weight regain The GLP-1 market is predicted to increase to $16.8B by 2028, pushing organizations to adapt and grow along with it